Norway Allergy Diagnostics And Therapeutics Market Size & Outlook
Norway allergy diagnostics and therapeutics market, 2018-2030 (US$M)
Related Markets
Norway allergy diagnostics and therapeutics market highlights
- The Norway allergy diagnostics and therapeutics market generated a revenue of USD 108.6 million in 2023 and is expected to reach USD 161.4 million by 2030.
- The Norway market is expected to grow at a CAGR of 5.8% from 2024 to 2030.
- In terms of segment, inhaled was the largest revenue generating allergen type in 2023.
- Other Allergens is the most lucrative allergen type segment registering the fastest growth during the forecast period.
Allergy diagnostics and therapeutics market data book summary
| Market revenue in 2023 | USD 108.6 million |
| Market revenue in 2030 | USD 161.4 million |
| Growth rate | 5.8% (CAGR from 2023 to 2030) |
| Largest segment | Inhaled |
| Fastest growing segment | Other Allergens |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inhaled, Drug, Other Allergens, Food |
| Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global allergy diagnostics and therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany allergy diagnostics and therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,394.7 million by 2030.
Inhaled was the largest segment with a revenue share of 49.45% in 2023. Horizon Databook has segmented the Norway allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
The allergy diagnostics and therapeutics market is projected to showcase significant growth over the forecast period due to rising expansion of healthcare infrastructure, growing pharmaceutical sector, and increasing investment in R&D activities.
Rising urbanization and industrialization have led to an increase in the level of air pollution, which has increased the prevalence of respiratory allergies, such as asthma and chronic cough. Such factors have led to the rising demand for novel drugs and diagnostic procedures, thereby boosting the market. Some of the key players in the market are GSK, Pfizer, Inc., and Danaher.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Diagnostics And Therapeutics Market Scope
Allergy Diagnostics And Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway allergy diagnostics and therapeutics market size, by allergen type, 2018-2030 (US$M)
Norway Allergy Diagnostics And Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
